NeoGenomics Presents Clinical Data for its RaDaR Lung Cancer Assay

NeoGenomics’ liquid biopsy-focused subsidiary Inivata has newly published data supporting its RaDaR (residual disease and recurrence) liquid biopsy test in patients with early-stage nonsmall-cell lung cancer (NSCLC).

The data from a UK study showed that when the RaDaR assay was used to analyze the blood samples of 88 patients with stage I to III NSCLC, it found circulating tumor DNA (ctDNA) that was highly predictive of subsequent clinical recurrence.

The ctDNA detection preceded clinical detection of recurrence of the primary tumor by about seven months, “highlighting the potential of the assay to identify patients who may benefit from further early therapeutic intervention,” the company said.

Ft. Myers, Fla.-based NeoGenomics provides cancer-focused genetic testing services and international oncology contract research services.